The project will generate the currently missing knowledge on the molecular physiology and pathophysiology of prostate cancer enabling:

• The definition of biomarkers based on disease pathophysiology.
• Completely novel approaches towards therapies.

PROMOTE contributes also to European Innovation capacity will be solidly achieved via: 

1) the introduction of analytical integration pipelines for multi-layer and multi-omics datasets,

2) the delivery of clinically relevant tools to guide PCa intervention, including integrative models for guiding treatment and making the best use of existing therapies. Predicted novel molecularly driven drug targets for advanced PCa, will be an additional compendium to support further research in the field of PCa, and

3) decrease the burden of European society and healthcare through efficient use of medical imaging and effective drug repurposing and the introduction of more effective therapeutic options, hence decreasing treatment costs.